SiBone (NASDAQ:SIBN) Director Jeffrey Dunn Sells 20,000 Shares of Stock

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $18.91, for a total value of $378,200.00. Following the completion of the transaction, the director directly owned 16,057 shares in the company, valued at approximately $303,637.87. The trade was a 55.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

SiBone Stock Down 2.7%

NASDAQ:SIBN traded down $0.52 during mid-day trading on Thursday, reaching $18.64. The stock had a trading volume of 632,446 shares, compared to its average volume of 500,274. The stock has a market cap of $826.68 million, a P/E ratio of -54.82 and a beta of 0.70. The business’s 50 day moving average is $18.09 and its 200 day moving average is $15.55. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $21.89.

SiBone (NASDAQ:SIBN) last posted its earnings results on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.06. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. The company had revenue of $56.01 million during the quarter, compared to the consensus estimate of $55.34 million. As a group, sell-side analysts predict that SiBone will post -0.4 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on SIBN shares. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Truist Financial reissued a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of SiBone in a research report on Tuesday, August 4th. TD Cowen upped their target price on shares of SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Finally, UBS Group boosted their price objective on shares of SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, SiBone currently has a consensus rating of “Moderate Buy” and an average price target of $24.17.

Institutional Trading of SiBone

Several institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada raised its stake in SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after acquiring an additional 736 shares in the last quarter. Versant Capital Management Inc boosted its stake in shares of SiBone by 102.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after purchasing an additional 887 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of SiBone by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after purchasing an additional 1,053 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of SiBone by 42.3% in the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock worth $70,000 after purchasing an additional 1,061 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of SiBone by 4.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,159 shares of the company’s stock worth $733,000 after purchasing an additional 1,459 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.